[1] Joseph K R,Edirimanne S,Eslick G D. The association between breast cancer and thyroid cancer:a meta-analysis[J]. Breast Cancer Res Treat,2015,152(1):173-181.
[2] Adjadj E,Rubino C,Shamsaldim A,et al. The risk of multiple primary breast and thyroid carcinomas[J]. Cancer,2003,98(6):1309-1317.
[3] Park C M,Lee Y D,Oh E M,et al. The prognosis and treatment of primary thyroid cancer occurred in breast cancer patients:comparison with ordinary thyroid cancer[J]. Ann Surg Treat Res,2014,86(4):169-176.
[4] Subramanian S,Goldstein D P,Parlea L,et al. Second primary malignancy risk in thyroid cancer survivors:a systematic review and meta-analysis[J]. Thyroid,2007,17(12):1277-1288.
[5] Jerzak K J,Cockburn J, Pond G R,et al. Thyroid hormone receptor α in breast cancer:prognostic and therapeutic implications[J]. Breast Cancer Res Treat,2015,149(1):293-301.
[6] Prinzi N,Baldini E,Sorrenti S,et al. Prevalence of breast cancer in thyroid diseases:results of a cross-sectional study of 3,921 patients[J]. Breast Cancer Res Treat,2014,144(3):683-688.
[7] 陈剑, 吴毅. 甲状腺癌与乳腺癌关系的研究进展[J]. 中国癌症杂志,2011,21(2):148-152.
[8] Gao Q,Zheng Y,Wang B,et al. Three metachronous cases of HER2-Positive breast cancer accompanied with thyroid cancer[J]. Breast Care (Basel),2014,9(5):360-363.
[9] Sawka A M,Thabane L,Parlea L,et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer:a systematic review and meta-analysis[J]. Thyroid,2009,19(5):451-457.
[10] Yu G P,Schantz S P,Neugut A I,et al. Incidences and trends of second cancers in female breast cancer patients:a fixed inception cohort-based analysis (United States)[J]. Cancer Causes Control,2006,17(4):411-420.
[11] 朱玉平, 许坚,韦正波.甲状腺和乳腺多重癌的临床分析[J].中国煤炭工业医学杂志,2016,19(5):657-660.
[12] 马亚凌, 陈静,张雨. 甲状腺癌超声征象与病理组织学类型及临床分期的联系[J].中华肿瘤防治杂志,2016,23(S1):64-65.
[13] 杨尽梅, 邵庆华,王嫱,等.体检人群甲状腺结节患病危险因素的相关性研究[J].中华肿瘤防治杂志,2016,23(S1):91-92. |
